Galapagos discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna on 21 October. Furthermore, Galapagos presents a poster disclosing favorable Phase 1 results with GLPG1205, the first clinical compound ever developed against target GPR84.
Drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot immediately be introduced in large clinical trials, but require rational exploration in tailored early phase clinical studies, with biomarkers that are fit-to-purpose.
Treeway and LACDR at the University of Leiden join forces and form a collaboration focused on the optimization of clinical trial designs and data-analysis for ALS (Amyotrophic Lateral Sclerosis) through the use of population disease progression models. Furthermore both parties aim to obtain a better understanding of the disease by developing ALS physiology-based disease models and to test the effect of interventions in the different identified pathways.
Pluriomics announced that it has raised €4 million in a Series A round led by Vesalius Biocapital (VBC) with additional financing from InnovationQuarter (IQ) and Société régionale d'Investissement de Wallonie (SRIW).
The funds will be used to further develop Pluriomics’ innovative stem cell derived cardiomyocytes and assays and to commercialize these technologies. Pluriomics will strengthen its R&D and commercial team in Leiden while setting-up a production facility in Gosselies, thereby leveraging the expertise available in South Holland and Wallonia.
Biotech company Pharming Group NV and Swedish Orphan Biovitrum AB (publ) or “Sobi”, announced the amendment and extension of the Ruconest® distribution agreement between Pharming and Sobi. Effective immediately, Pharming will focus on direct commercialization in Austria, Germany and Netherlands, and Sobi will extend its Ruconest® sales territory with the addition of Azerbaijan, Belarus, Georgia, Kazakhstan, Russia, Serbia and Ukraine.
On October 10, 2014, the groundbreaking ceremony for the Biotech Training Facility (BTF) took place in Leiden at the Bio Science Park.This facility is aimed at the training of personnel for the biotechnology and the pharma industry. The BTF will be a real GMP production plant, where all unit operations that are important for the industry will be present. People can get the training they need there, in a standard series of courses or in tailor made training sessions.The first students can enter the BTF in Q4 2015.
Prosensa begins NDA submission to the FDA for exon-skipping drug drisapersen to treat Duchenne muscular dystrophyPublished : Friday, October 10, 2014
Prosensa Holding N.V. the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that it has commenced the submission process for a New Drug Application (NDA) regulatory filing to the United States Food and Drug Administration (FDA) for its lead exon-skipping drug candidate, drisapersen, for treating Duchenne muscular dystrophy (DMD). The drug received "Fast Track status" from the FDA, making it eligible for a rolling review of an NDA and was also granted "Breakthrough Therapy Designation" in June 2013.
Dutch biotech MIMETAS B.V. announced that it has raised 5.2 million dollar to fund its expansion as a global leader in organ-on-a-chip technology. Venture capital investors Zeeuws Investerings Fonds (ZIF) and Participatiemaatschapij Oost Nederland (PPM Oost) have joined forces with national and regional partners to fund development and sales of MIMETAS’ unique 3D disease- and tissue modelling technologies.
LSP (Life Sciences Partners) announced that it has raised EUR 80 mln (USD 100 mln) for its new fund LSP 5. This fund will continue LSP’s proven and successful strategy of investing in emerging private companies with innovative medicines and medical technologies. Investors stated that they selected LSP because of its impact on healthcare and its consistently strong financial performance.
to-BBB, a biopharmaceutical company pioneering treatments for devastating brain diseases, today announced significant additions to complete its new management team as well as changing its name from to-BBB technologies B.V. to BBB Therapeutics B.V. Dr. Ferdinand (Ferd) Massari and Dr. Pericles (Perry) Calias have joined BBB as Chief Medical Officer and as Chief Scientific Officer, respectively. Completing the management team are recently appointed Chief Executive Officer Dr. Anders Harfstrand, and Chief Financial Officer Leon Kruimer and Chief Business Officer Dr. Carlos de Sousa, both of whom joined the company in 2014.
Mymetics’ promising HIV vaccine candidate obtains funding to begin study at Texas Biomedical Research InstitutePublished : Monday, September 29, 2014
Mymetics Corporation (OTCQB: MYMX), a pioneer in the research and development of virosome-based vaccines to prevent transmission of human infectious diseases across mucosal membranes, announced today that its innovative HIV vaccine candidate will enter a new preclinical trial to confirm excellent results obtained in a previous trial.
Prosensa extends the re-dosing of drisapersen in Europe in patients with Duchenne muscular dystrophyPublished : Friday, September 26, 2014
Prosensa Holding N.V., the biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, announced that it has extended its comprehensive program of re-dosing of drisapersen in patients with Duchenne muscular dystrophy (DMD) into Europe, with the PRO051-02/DMD114673 sites re-opening, beginning with Belgium. This follows quickly on the re-dosing program that began in the United States (US) last week.
Last Saturday during the Night of Arts & Knowledge, the Rode Loper films about the chain of drug development at Leiden Bio Science Park were launched. The 10 short films show in an attractive way the relevant steps involved in drug development. From academic fundamental research to various steps in drug development by companies and institutions at the science park, to administration to the patient at the LUMC.
> Read more in Dutch
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe